Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "Glaucoma"

48 News Found

ENTOD Pharmaceuticals launches glaucoma awareness campaign
Public Health | March 08, 2022

ENTOD Pharmaceuticals launches glaucoma awareness campaign

Raising awareness about glaucoma is crucial in India where it is the leading cause of irreversible blindness with at least 12 million people affected and almost 1.2 million people blind from the disease


Bayer seals $300 million Perfuse deal
News | June 18, 2026

Bayer seals $300 million Perfuse deal

Secures high-stakes glaucoma drug in up to $2.45b bet on eye care pipeline


Remidio’s InstaEyeClinic wins first position at Andhra Pradesh MedTech Innovation Challenge
Medical Device | May 28, 2026

Remidio’s InstaEyeClinic wins first position at Andhra Pradesh MedTech Innovation Challenge

The device screens for conditions like diabetic retinopathy, glaucoma, age-related macular degeneration, cataract and refractive error, in under ten minutes per patient


Decoding teleophthalmology role in transforming last-mile eye care in India
Opinion | May 20, 2026

Decoding teleophthalmology role in transforming last-mile eye care in India

By leveraging digital screening and remote consultation, the medical community is moving beyond the confines of the clinic


Eye-Q upgrades advanced affordable eye care facility in Lucknow
Hospitals | May 09, 2026

Eye-Q upgrades advanced affordable eye care facility in Lucknow

The upgraded Rajajipuram centre now features enhanced retina services and advanced OCT technology


Bayer strikes $2.45 billion deal for breakthrough blindness drug developer Perfuse Therapeutics
News | May 07, 2026

Bayer strikes $2.45 billion deal for breakthrough blindness drug developer Perfuse Therapeutics

The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy


Vision 360 brings academia, industry together to advance ophthalmic therapies
Healthcare | April 25, 2026

Vision 360 brings academia, industry together to advance ophthalmic therapies

VESCOP, ENTOD Pharmaceuticals, and APTI-MSB host the event to bridge lab-to-clinic gap in eye care


Lupin completes acquisition of VISUfarma
News | April 02, 2026

Lupin completes acquisition of VISUfarma

The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe


Axol Bioscience acquires ophthalmology business from Newcells Biotech
News | February 19, 2026

Axol Bioscience acquires ophthalmology business from Newcells Biotech

Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models


Alembic announces USFDA final approval for Travoprost Ophthalmic Solution USP, 0.004%
Drug Approval | December 20, 2025

Alembic announces USFDA final approval for Travoprost Ophthalmic Solution USP, 0.004%

Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension